Intracerebroventricular Cerliponase Alfa for CLN2 Disease: Clinical Practice Considerations from US Clinics

被引：0
|
作者：
de los Reyes, E.
Lehwald, L.
Wang, R.
Augustine, E.
Berry-Kravis, E.
Butler, K.
Cormier, N.
Demarest, S.
Lu, S.
Madden, J.
Olaya, J.
See, S.
Vierhile, A.
Yang, A.
Leal-Pardinas, F.
机构：
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
Rare Diseases;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
205
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [41] Progressive retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in classic late-infantile CLN2 disease
    Atiskova, Yevgeniya
    Schwering, Christoph
    Wildner, Jan
    Spartalis, Christoph
    Schuttauf, Frank
    Bartsch, Udo
    Wibbeler, Eva
    Nickel, Miriam
    Spitzer, Martin
    Schulz, Angela
    Dulz, Simon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [42] Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study
    Schulz, Angela
    Specchio, Nicola
    Reyes, Emily de los
    Gissen, Paul
    Nickel, Miriam
    Trivisano, Marina
    Aylward, Shawn C.
    Chakrapani, Anupam
    Schwering, Christoph
    Wibbeler, Eva
    Westermann, Lena Marie
    Ballon, Douglas J.
    Dyke, Jonathan P.
    Cherukuri, Anu
    Bondade, Shailesh
    Slasor, Peter
    Pfeffer, Jessica Cohen
    LANCET NEUROLOGY, 2024, 23 (01): : 60 - 70
  • [43] Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment
    Amanda Mortensen
    Eva M. Raebel
    Samantha Wiseman
    Orphanet Journal of Rare Diseases, 17
  • [44] A long-term observation of ophthalmology assessment in atypical CLN2 patients receiving ICV cerliponase alfa treatment
    Kao, Audrey
    Chang, Harriet
    Bhola, Rahul
    Wang, Raymond Y.
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [45] Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment
    Mortensen, Amanda
    Raebel, Eva M.
    Wiseman, Samantha
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
  • [46] Intravitreal Cerliponase alfa for the treatment of CLN2 type Batten Disease related retinal dystrophy: A first in man report of ocular enzyme replacement
    Wawrzynski, James
    Gissen, Paul
    Bowman, Richard
    Bower, Rebecca
    Gan, Chin
    Harding, Louise
    Mortensen, Amanda
    Thompson, Dorothy
    Henderson, Robert
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [47] Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)
    Dulz, Simon
    Schwering, C.
    Wildner, Jan
    Spartalis, Christoph
    Schuettauf, Frank
    Bartsch, Udo
    Wibbeler, Eva
    Nickel, Miriam
    Spitzer, Martin Stephan
    Atiskova, Yevgeniya
    Schulz, Angela
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2023, 107 (10) : 1478 - 1483
  • [48] Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)
    Dulz, Simon
    Schwering, C.
    Wildner, Jan
    Spartalis, Christoph
    Schuettauf, Frank
    Bartsch, Udo
    Wibbeler, Eva
    Nickel, Miriam
    Spitzer, Martin Stephan
    Atiskova, Yevgeniya
    Schulz, Angela
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2022,
  • [49] Analysis of drug-specific antibody response against cerliponase alfa in CLN2 patients by applying a novel two-step assay
    Westermann, Lena Marie
    Junginger, Zoe-Isabella
    Mann, Anna Marei
    Tolosa, Eva
    Schulz, Angela
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [50] LONG-TERM SAFETY AND EFFICACY OF INTRACEREBROVENTRICULAR ENZYME REPLACEMENT THERAPY WITH CERLIPONASE ALFA IN CHILDREN CLN WITH 2 DISEASE: INTERIM RESULTS FROM AN ONGOING MULTICENTER, MULTINATIONAL EXTENSION STUDY
    Specchio, N.
    Schulz, A.
    Gissen, P.
    de los Reyes, E.
    Cahan, H.
    Slasor, P.
    Ajayi, T.
    Jacoby, D.
    EPILEPSIA, 2017, 58 : S32 - S32
12345